New diagnostic imaging tool monitors fate of cell therapies in cancer patients

June 20 2023

A pilot study at University of California San Diego School of Medicine debuts a novel method to monitor the survival of a cancer cell therapy using a fluorine-based nanoemulsion agent to "tag" cells prior to patient
infusion. The tag enables magnetic resonance imaging (MRI) detection of a cell therapy product (i.e. engineered T cells) post-delivery.

The study publishes June 20, 2023 in Journal for ImmunoTherapy of Cancer and was led by Eric Ahrens, Ph.D., professor of radiology at UC San Diego School of Medicine.

This technology opens the door for real-time monitoring of cellular graft health in any type of adoptive cell therapy. The findings may be useful for cell product developers and clinicians alike.


Provided by University of California - San Diego


This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.